SCHEMBL1284458

SCHEMBL1284458

CCOCc1cc2cc(Cl)ccc2o/c1=N\c1ccc(C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.37
THRB P10828 1/20 0.37
KDM4E B2RXH2 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HSD17B10 Q99714 2/20 0.37
LMNA P02545 3/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 2/20 0.36
PKM P14618 2/20 0.36
KMT2A Q03164 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
BRCA1 P38398 1/20 0.36
CASP7 P55210 1/20 0.36
MAOB P27338 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1284459 1.00 TP53 (0.37) TP53THRBKDM4ESMN1; SMN2HSD17B10
SCHEMBL1285404 0.94 KDM4E (0.39) KDM4ESMN1; SMN2HSD17B10KMT2AMAOB
SCHEMBL1285402 0.94 KDM4E (0.39) KDM4ESMN1; SMN2HSD17B10KMT2AMAOB
SCHEMBL1285238 0.90 KDM4E (0.36) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1285239 0.90 KDM4E (0.36) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1284818 0.90 KDM4E (0.36) TP53KDM4ESMN1; SMN2HSD17B10NPC1
SCHEMBL1284817 0.90 KDM4E (0.36) TP53KDM4ESMN1; SMN2HSD17B10NPC1
SCHEMBL1285044 0.89 KDM4E (0.38) TP53KDM4ESMN1; SMN2HSD17B10NPC1
SCHEMBL1285043 0.89 KDM4E (0.38) TP53KDM4ESMN1; SMN2HSD17B10NPC1
SCHEMBL1284957 0.89 MAOB (0.45) TP53KDM4ESMN1; SMN2HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383843-B2 Method for preparing a coumarin compound, chromene compound, and method for preparing a chromene compound KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-02-26 US disclosed
US-20120088923-A1 METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND KAOHSIUNG MEDICAL UNIVERSITY (TW) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088923-A1 METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND CYP3A7, CYP2A7, F7 TP53 1672/4885THRB 3312/4885KDM4E 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.